JP2010163438A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010163438A5 JP2010163438A5 JP2010030683A JP2010030683A JP2010163438A5 JP 2010163438 A5 JP2010163438 A5 JP 2010163438A5 JP 2010030683 A JP2010030683 A JP 2010030683A JP 2010030683 A JP2010030683 A JP 2010030683A JP 2010163438 A5 JP2010163438 A5 JP 2010163438A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- fragment
- seq
- composition
- epitope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000012634 fragment Substances 0.000 claims 37
- 210000004881 tumor cell Anatomy 0.000 claims 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 8
- 101100369076 Mus musculus Tdgf1 gene Proteins 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 102000012545 EGF-like domains Human genes 0.000 claims 2
- 108050002150 EGF-like domains Proteins 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- 238000003018 immunoassay Methods 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010061968 Gastric neoplasm Diseases 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000025189 neoplasm of testis Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 230000004565 tumor cell growth Effects 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 208000025421 tumor of uterus Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 claims 1
Claims (31)
- 配列番号1または配列番号2のエピトープと特異的に結合し、かつCriptoシグナル伝達を調節し得る、抗体またはそのフラグメント。
- 配列番号1または配列番号2のエピトープと特異的に結合し、かつ腫瘍増殖を調節し得る、抗体またはそのフラグメント。
- 前記抗体またはフラグメントが、A40G12.8、A8H3.1、A27F6.1およびA6C12.11からなる群より選択される参照抗体と同じエピトープに結合する、請求項1に記載の抗体またはフラグメント。
- 前記抗体またはフラグメントが、A27F6.1、B6G7.10およびA8G3.5からなる群より選択される参照抗体と同じエピトープに結合する、請求項2に記載の抗体またはフラグメント。
- 前記エピトープが、配列番号1または配列番号2のEGF様ドメインまたはシステインリッチドメイン内にある、請求項1〜4のいずれか1項に記載の抗体またはフラグメント。
- 以下の抗体:A6C12.11、A6F8.6、A7H1.19、A8F1.30、A8G3.5、A8H3.1、A8H3.2、A19A10.30、Al0B2.18、A27F6.1、A40G12.8、A2D3.23、A7A10.29、A9G9.9、A15C12.10、A15E4.14、A17A2.16、A17C12.28、A17G12.1、A17H6.1、A18B3.11、A19E2.7、B3F6.17、B6G7.10およびB11H8.4のいずれか1つが結合するエピトープの群より選択されるエピトープに特異的に結合する、抗体またはそのフラグメント。
- A6F8.6(ATCC登録番号PTA−3318)、A8G3.5(ATCC登録番号PTA−3317)、A8H3.1(ATCC登録番号PTA−3315)、Al0B2.18(ATCC登録番号PTA−3311)、A27F6.1(ATCC登録番号PTA−3310)、A40G12.8(ATCC登録番号PTA−3316)、A17G12.1(ATCC登録番号PTA−3314)、A18B3.11(ATCC登録番号PTA−3312)、B3F6.17(ATCC登録番号PTA−3319)およびB6G7.10(ATCC登録番号PTA−3313)からなる群より選択されるハイブリドーマによって産生される抗体またはそのフラグメント。
- 配列番号1または配列番号2の細胞外ドメイン内のエピトープに特異的に結合する、抗体またはそのフラグメント。
- 配列番号1または配列番号2のアミノ酸残基114〜アミノ酸残基150にまたがるCriptoのシステインリッチドメインに含まれるエピトープに特異的に結合する、抗体またはそのフラグメント。
- 配列番号1または配列番号2のリガンド/レセプター結合ドメイン内のエピトープに特異的に結合する、抗体またはそのフラグメント。
- 前記抗体またはフラグメントが、A6C12.11、A6F8.6、A8G3.5、A19A10.30、A8H3.1、A27F6.1、A40G12.8、A17G12.1、A18B3.11およびB6G7.10からなる群より選択される参照抗体と同じエピトープに結合する、請求項9または請求項10に記載の抗体またはフラグメント。
- 配列番号1または配列番号2のEGF様ドメイン内のエピトープに特異的に結合する、抗体またはそのフラグメント。
- 前記抗体またはフラグメントが、A40G12.8、A8H3.1、A27F6.1、B6G7.10、A17G12.1およびA18B3.11からなる群より選択される参照抗体と同じエピトープに結合する、請求項12に記載の抗体またはフラグメント。
- 前記フラグメントが、Fabフラグメント、Fab’フラグメント、F(ab’) 2 フラグメントおよびFvフラグメントからなる群より選択される、請求項1〜13のいずれか1項に記載の抗体のフラグメント。
- 前記抗体が単鎖抗体である、請求項1〜14のいずれか1項に記載の抗体。
- 前記抗体がモノクローナル抗体である、請求項1〜15のいずれか1項に記載の抗体またはフラグメント。
- 前記抗体がヒト抗体またはヒト化抗体である、請求項1〜16のいずれか1項に記載の抗体またはフラグメント。
- 前記抗体またはフラグメントが化学療法剤に結合体化される、請求項1〜17のいずれか1項に記載の抗体またはフラグメント。
- 前記抗体またはフラグメントが関連のポリペプチドに融合される、請求項1〜18のいずれか1項に記載の抗体またはフラグメント。
- 請求項1〜19のいずれか1項に記載の抗体またはフラグメント少なくとも1つと、薬学的に受容可能な賦形剤とを含む、組成物。
- 非結合体化化学療法剤をさらに含む、請求項20に記載の組成物。
- 腫瘍細胞の増殖の調節に使用するための、請求項1〜19のいずれか1項に記載の抗体またはフラグメントを含む組成物、または請求項20もしくは請求項21に記載の組成物。
- Criptoを過剰発現する腫瘍細胞を有する被験体の処置に使用するための、請求項1〜19のいずれか1項に記載の抗体またはフラグメントを含む組成物、または請求項20もしくは請求項21に記載の組成物。
- 所望でない細胞増殖の低下に使用するための、請求項1〜19のいずれか1項に記載の抗体またはフラグメントを含む組成物、または請求項20もしくは請求項21に記載の組成物。
- 前記腫瘍細胞が、乳癌細胞、精巣腫瘍細胞、結腸癌細胞、肺癌細胞、卵巣腫瘍細胞、膀胱腫瘍細胞、子宮腫瘍細胞、頸部腫瘍細胞、膵臓腫瘍細胞、および胃腫瘍細胞からなる群より選択される、請求項22または23に記載の組成物。
- 組織がCriptoを発現するかどうかを決定する方法であって、該方法は、請求項1〜19のいずれか1項に記載の抗体またはフラグメントを用いるイムノアッセイにおいて、被験体由来の組織を分析する工程を包含する、方法。
- 細胞株がCriptoを過剰発現するかどうかを決定する方法であって、該方法は、請求項1〜19のいずれか1項に記載の抗体またはフラグメントを用いるイムノアッセイにおいて、該細胞株を分析する工程を包含する、方法。
- 請求項1〜19のいずれか1項に記載の抗体またはフラグメントを製造する方法であって、該方法は、該抗体またはフラグメントを組換え的に産生する工程を包含する、方法。
- Criptoを発現する腫瘍細胞に化学療法剤を送達するための組成物であって、該組成物は、化学療法剤に結合体化されたCriptoをインターナライズし得るモノクローナル抗体またはそのフラグメントを含有し、該組成物が該細胞に送達されることを特徴とする、組成物。
- 前記抗体またはフラグメントが、配列番号1または配列番号2のアミノ酸残基46〜62にまたがる細胞外ドメインに含まれるエピトープに結合する、請求項29に記載の組成物。
- 明細書に記載の発明。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28678201P | 2001-04-26 | 2001-04-26 | |
US29302001P | 2001-05-17 | 2001-05-17 | |
US30109101P | 2001-06-26 | 2001-06-26 | |
US36700202P | 2002-03-22 | 2002-03-22 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009025420A Division JP4575983B2 (ja) | 2001-04-26 | 2009-02-05 | Criptoをブロックする抗体およびその使用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010163438A JP2010163438A (ja) | 2010-07-29 |
JP2010163438A5 true JP2010163438A5 (ja) | 2011-04-07 |
Family
ID=27501437
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002585468A Expired - Fee Related JP4307845B2 (ja) | 2001-04-26 | 2002-04-17 | Criptoをブロックする抗体およびその使用 |
JP2005202361A Pending JP2005314436A (ja) | 2001-04-26 | 2005-07-11 | Criptoをブロックする抗体およびその使用 |
JP2009025420A Expired - Fee Related JP4575983B2 (ja) | 2001-04-26 | 2009-02-05 | Criptoをブロックする抗体およびその使用 |
JP2010030683A Withdrawn JP2010163438A (ja) | 2001-04-26 | 2010-02-15 | Criptoをブロックする抗体およびその使用 |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002585468A Expired - Fee Related JP4307845B2 (ja) | 2001-04-26 | 2002-04-17 | Criptoをブロックする抗体およびその使用 |
JP2005202361A Pending JP2005314436A (ja) | 2001-04-26 | 2005-07-11 | Criptoをブロックする抗体およびその使用 |
JP2009025420A Expired - Fee Related JP4575983B2 (ja) | 2001-04-26 | 2009-02-05 | Criptoをブロックする抗体およびその使用 |
Country Status (34)
Country | Link |
---|---|
US (6) | US7531174B2 (ja) |
EP (3) | EP1974749B1 (ja) |
JP (4) | JP4307845B2 (ja) |
KR (1) | KR100592357B1 (ja) |
CN (1) | CN100352501C (ja) |
AR (3) | AR037223A1 (ja) |
AT (2) | ATE420659T1 (ja) |
BG (1) | BG108363A (ja) |
BR (1) | BR0209254A (ja) |
CA (2) | CA2715570A1 (ja) |
CL (1) | CL2009002199A1 (ja) |
CY (1) | CY1108960T1 (ja) |
CZ (1) | CZ20033208A3 (ja) |
DE (1) | DE60230868D1 (ja) |
DK (1) | DK1390389T3 (ja) |
EA (1) | EA007469B1 (ja) |
EE (1) | EE200300528A (ja) |
ES (1) | ES2321065T3 (ja) |
GE (1) | GEP20074091B (ja) |
HK (1) | HK1058935A1 (ja) |
HU (1) | HUP0501113A3 (ja) |
IS (1) | IS2662B (ja) |
MX (1) | MXPA03009797A (ja) |
MY (2) | MY157382A (ja) |
NO (1) | NO20034805L (ja) |
NZ (1) | NZ566268A (ja) |
PL (1) | PL207087B1 (ja) |
PT (1) | PT1390389E (ja) |
RS (2) | RS20110024A (ja) |
SG (1) | SG157951A1 (ja) |
SI (1) | SI1390389T1 (ja) |
SK (1) | SK14432003A3 (ja) |
TR (1) | TR200301846T2 (ja) |
WO (1) | WO2002088170A2 (ja) |
Families Citing this family (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPR395801A0 (en) | 2001-03-26 | 2001-04-26 | Austin Research Institute, The | Antibodies against cancer |
US20090123470A1 (en) * | 2001-03-26 | 2009-05-14 | The Macfarlane Burnet Istitute For Medical Research And Public Health Ltd. | Antibodies Against Cancer |
US7582299B2 (en) | 2001-04-26 | 2009-09-01 | Biogen Idec Ma Inc. | Cripto-specific antibodies |
DE60230868D1 (de) * | 2001-04-26 | 2009-03-05 | Biogen Inc | Criptoblockierende antikörper und deren verwendung |
JP2005520566A (ja) * | 2002-03-22 | 2005-07-14 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Cripto特異的抗体 |
US20050276812A1 (en) | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Antibody-drug conjugates and methods |
EP1641826A2 (en) | 2003-06-27 | 2006-04-05 | Biogen Idec MA Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
ATE437950T1 (de) * | 2003-09-15 | 2009-08-15 | Res Dev Foundation | Cripto-antagonismus von activin und tgf-b signalisierung |
SG195524A1 (en) | 2003-11-06 | 2013-12-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
CA2545603A1 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto |
AU2005286607B2 (en) | 2004-09-23 | 2011-01-27 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
EP2311880A3 (en) * | 2005-01-05 | 2011-07-27 | Biogen Idec MA Inc. | Cripto binding molecules |
WO2006074399A2 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
WO2008014426A2 (en) * | 2006-07-28 | 2008-01-31 | Children's Memorial Hospital | Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells |
CA2688563A1 (en) * | 2007-06-01 | 2008-12-11 | Biogen Idec Ma Inc. | Cripto binding molecules |
CA2719385A1 (en) * | 2008-04-21 | 2009-10-29 | Merck Sharp & Dohme Corp. | Pancreatic beta-cell mass biomarker |
CA2743057C (en) * | 2008-11-07 | 2019-11-26 | Research Development Foundation | Compositions and methods for the inhibition of cripto/grp78 complex formation and signaling |
US8470980B2 (en) | 2009-09-09 | 2013-06-25 | Centrose, Llc | Extracellular targeted drug conjugates |
DK2528625T3 (da) | 2010-04-15 | 2013-10-14 | Spirogen Sarl | Pyrrolobenzodiazepiner og konjugater deraf |
CN114246952A (zh) | 2010-06-08 | 2022-03-29 | 基因泰克公司 | 半胱氨酸改造的抗体和偶联物 |
US20120121615A1 (en) | 2010-11-17 | 2012-05-17 | Flygare John A | Alaninyl maytansinol antibody conjugates |
EP2686020B1 (en) | 2011-03-17 | 2017-02-22 | The University of Birmingham | Re-directed immunotherapy |
TWI636793B (zh) | 2011-04-21 | 2018-10-01 | 西雅圖遺傳學公司 | 新穎結合劑-藥物接合物(ADCs)及其用途(二) |
ES2567276T3 (es) | 2011-05-12 | 2016-04-21 | Genentech, Inc. | Método de LC-MS/MS de monitoreo de múltiples reacciones para detectar anticuerpos terapéuticos en muestras de animales usando péptidos de cambio de marco |
US9738707B2 (en) | 2011-07-15 | 2017-08-22 | Biogen Ma Inc. | Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto |
CN103987407B (zh) | 2011-10-14 | 2016-08-24 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓及其偶联物 |
WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
ES2680153T3 (es) | 2012-10-12 | 2018-09-04 | Adc Therapeutics Sa | Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas |
CA2885340C (en) | 2012-10-12 | 2016-11-08 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
ES2660029T3 (es) | 2012-10-12 | 2018-03-20 | Medimmune Limited | Conjugados de anticuerpo-pirrolobenzodiazepinas |
RS57694B1 (sr) | 2012-10-12 | 2018-11-30 | Adc Therapeutics Sa | Pirolobenzodiazepin - anti-psma konjugati antitela |
HUE039329T2 (hu) | 2012-10-12 | 2018-12-28 | Adc Therapeutics Sa | Pirrolobenzodiazepin-antitest konjugátumok |
JP6392763B2 (ja) | 2012-10-12 | 2018-09-19 | エイディーシー・セラピューティクス・エス・アーAdc Therapeutics Sa | ピロロベンゾジアゼピン−抗体結合体 |
MX364327B (es) | 2012-10-12 | 2019-04-23 | Medimmune Ltd | Conjugados del anticuerpo pirrolobenzodiazepina - anti-cd22. |
WO2014096365A1 (en) | 2012-12-21 | 2014-06-26 | Spirogen Sàrl | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
ES2658888T5 (es) | 2012-12-21 | 2021-10-19 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas |
AU2014230735B2 (en) | 2013-03-13 | 2018-03-15 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
JP6340019B2 (ja) | 2013-03-13 | 2018-06-06 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピン及びそのコンジュゲート |
NZ710745A (en) | 2013-03-13 | 2019-03-29 | Genentech Inc | Pyrrolobenzodiazepines and conjugates thereof |
EA201690195A1 (ru) | 2013-08-12 | 2016-05-31 | Дженентек, Инк. | Конъюгатные соединения антитело-лекарство на основе димера 1-(хлорметил)-2,3-дигидро-1h-бензо[e]индола и способы применения и лечения |
US9950078B2 (en) | 2013-10-11 | 2018-04-24 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
WO2015052532A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
US9956299B2 (en) | 2013-10-11 | 2018-05-01 | Medimmune Limited | Pyrrolobenzodiazepine—antibody conjugates |
GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
PE20161394A1 (es) | 2013-12-16 | 2017-01-06 | Genentech Inc | Compuestos peptidomimeticos y sus conjugados de anticuerpo-farmaco |
MX371092B (es) | 2013-12-16 | 2020-01-16 | Genentech Inc | Compuestos peptidomimeticos y conjugados de anticuerpo-farmaco de los mismos. |
JP6980384B2 (ja) | 2013-12-16 | 2021-12-15 | ジェネンテック, インコーポレイテッド | 1−(クロロメチル)−2,3−ジヒドロ−1h−ベンゾ[e]インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法 |
BR112016014830A2 (pt) | 2013-12-23 | 2017-09-19 | Bayer Pharma AG | Conjugados de fármaco de anticorpo (adcs) com inibidores de ksp |
US10188746B2 (en) | 2014-09-10 | 2019-01-29 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
EP3191134B1 (en) | 2014-09-12 | 2019-11-20 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
BR112017003236A2 (pt) | 2014-09-12 | 2017-11-28 | Genentech Inc | anticorpos elaborados com cisteína, conjugados de droga e anticorpos, método de preparação de conjugado de droga e anticorpo e composição farmacêutica |
CR20170099A (es) | 2014-09-17 | 2017-07-19 | Genentech Inc | Pirrolobenzodiazepinas y conjugados de anticuerpos-disulfuro de las mismas |
MX2017006770A (es) | 2014-11-25 | 2018-02-09 | Adc Therapeutics Sa | Conjugados de pirrolobenzodiazepina y anticuerpo. |
EP3226909A1 (en) | 2014-12-03 | 2017-10-11 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
AU2016245328A1 (en) * | 2015-04-07 | 2017-10-12 | Paranta Biosciences Limited | A method of treating neoplasias |
GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
CA2990076A1 (en) | 2015-06-22 | 2016-12-29 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups |
MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
MA45326A (fr) | 2015-10-20 | 2018-08-29 | Genentech Inc | Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation |
GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
SG11201808167VA (en) | 2016-03-24 | 2018-10-30 | Bayer Pharma AG | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
US20170315132A1 (en) | 2016-03-25 | 2017-11-02 | Genentech, Inc. | Multiplexed total antibody and antibody-conjugated drug quantification assay |
GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
JP2019522633A (ja) | 2016-05-20 | 2019-08-15 | ジェネンテック, インコーポレイテッド | Protac抗体コンジュゲート及び使用方法 |
CN109313200B (zh) | 2016-05-27 | 2022-10-04 | 豪夫迈·罗氏有限公司 | 用于表征位点特异性抗体-药物缀合物的生物分析性方法 |
WO2017214024A1 (en) | 2016-06-06 | 2017-12-14 | Genentech, Inc. | Silvestrol antibody-drug conjugates and methods of use |
US11001636B2 (en) | 2016-06-15 | 2021-05-11 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies |
WO2018031662A1 (en) | 2016-08-11 | 2018-02-15 | Genentech, Inc. | Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof |
WO2018065501A1 (en) | 2016-10-05 | 2018-04-12 | F. Hoffmann-La Roche Ag | Methods for preparing antibody drug conjugates |
GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
WO2018114804A1 (de) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren |
KR20190099250A (ko) | 2016-12-21 | 2019-08-26 | 바이엘 악티엔게젤샤프트 | 효소적으로 절단가능한 기를 갖는 세포독성 활성제의 전구약물 |
IL310558A (en) | 2016-12-21 | 2024-03-01 | Bayer Pharma AG | Drug-antibody conjugates with enzymatically cleavable groups |
GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
PT3544636T (pt) | 2017-02-08 | 2021-05-04 | Medimmune Ltd | Conjugados de anticorpos-pirrolobenzodiazepinas |
WO2018192944A1 (en) | 2017-04-18 | 2018-10-25 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
KR20190141666A (ko) | 2017-04-20 | 2019-12-24 | 에이디씨 테라퓨틱스 에스에이 | 항-axl 항체-약물 접합체로의 병용 요법 |
AU2018285562B2 (en) | 2017-06-14 | 2024-01-18 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-CD19 ADC |
ES2906965T3 (es) | 2017-08-18 | 2022-04-21 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina |
WO2019060398A1 (en) | 2017-09-20 | 2019-03-28 | Ph Pharma Co., Ltd. | ANALOGUES OF THAILANSTATINE |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
WO2019232449A1 (en) | 2018-06-01 | 2019-12-05 | Eisai R&D Management Co., Ltd. | Splicing modulator antibody-drug conjugates and methods of use |
GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
TW202037381A (zh) | 2018-10-24 | 2020-10-16 | 瑞士商赫孚孟拉羅股份公司 | 綴合化學降解誘導劑及使用方法 |
WO2020123275A1 (en) | 2018-12-10 | 2020-06-18 | Genentech, Inc. | Photocrosslinking peptides for site specific conjugation to fc-containing proteins |
KR20210102274A (ko) | 2018-12-13 | 2021-08-19 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 헤르복시디엔 항체-약물 접합체 및 사용 방법 |
WO2020131697A2 (en) | 2018-12-17 | 2020-06-25 | Revitope Limited | Twin immune cell engager |
GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ207394A (en) * | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5208020A (en) * | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5780029A (en) | 1989-11-14 | 1998-07-14 | New York Medical College | Antidiotypic monoclonal antibodies for treatment of melanoma |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5256643A (en) | 1990-05-29 | 1993-10-26 | The Government Of The United States | Human cripto protein |
EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US5264557A (en) | 1991-08-23 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Polypeptide of a human cripto-related gene, CR-3 |
US6063379A (en) | 1993-12-09 | 2000-05-16 | Centro De Inmunologia Molecular | Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies |
US5981215A (en) * | 1995-06-06 | 1999-11-09 | Human Genome Sciences, Inc. | Human criptin growth factor |
ATE403001T1 (de) * | 1996-05-22 | 2008-08-15 | Viventia Biotech Inc | Antigenbindungsfragmente die spezifisch krebszellen nachweisen, nukleotide die für diese fragmente kodieren, und deren verwendung zur vorbeugung und zum nachweis von krebs |
IL125608A0 (en) | 1998-07-30 | 1999-03-12 | Yeda Res & Dev | Tumor associated antigen peptides and use of same as anti-tumor vaccines |
RS51309B (sr) | 1998-12-23 | 2010-12-31 | Pfizer Inc. | Humana monoklonalna antitela za ctla-4 |
US6335170B1 (en) | 1999-02-22 | 2002-01-01 | Torben F. Orntoft | Gene expression in bladder tumors |
WO2000058499A1 (fr) | 1999-03-30 | 2000-10-05 | Japan Tobacco Inc. | Procede pour la production d'anticorps monoclonal |
WO2000063693A1 (en) * | 1999-04-20 | 2000-10-26 | Kokolus William J | Improved method of identifying and locating immunobiologically-active linear peptides |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
JP2001046066A (ja) | 1999-08-03 | 2001-02-20 | Kyowa Hakko Kogyo Co Ltd | 新規な相補性決定領域を有するヒトvegf受容体kdrに対する抗体 |
EP1226177B1 (en) | 1999-10-29 | 2008-07-09 | Genentech, Inc. | Anti-prostate stem cell antigen (psca) antibody compositions and methods of use |
US6663613B1 (en) | 2000-01-25 | 2003-12-16 | Bacchus Vascular, Inc. | System and methods for clot dissolution |
WO2001064754A1 (fr) | 2000-03-03 | 2001-09-07 | Kyowa Hakko Kogyo Co., Ltd. | Anticorps a recombinaison genique et son fragment |
US6333410B1 (en) * | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
GB0020953D0 (en) | 2000-08-24 | 2000-10-11 | Smithkline Beecham Biolog | Vaccine |
CA2422814A1 (en) | 2000-09-18 | 2002-03-21 | Biogen, Inc. | Cripto mutant and uses thereof |
US7078176B2 (en) | 2001-01-26 | 2006-07-18 | The United States Of America As Represented By The Department Of Health And Human Serivices | Detection and quantification of Cripto-1 |
IL157142A0 (en) | 2001-01-29 | 2004-02-08 | Idec Pharma Corp | Modified antibodies and methods of use |
WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
AUPR395801A0 (en) * | 2001-03-26 | 2001-04-26 | Austin Research Institute, The | Antibodies against cancer |
DE60230868D1 (de) | 2001-04-26 | 2009-03-05 | Biogen Inc | Criptoblockierende antikörper und deren verwendung |
US7582299B2 (en) * | 2001-04-26 | 2009-09-01 | Biogen Idec Ma Inc. | Cripto-specific antibodies |
US20030148408A1 (en) * | 2001-09-18 | 2003-08-07 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US20040014690A1 (en) | 2002-02-13 | 2004-01-22 | Zhenkun Ma | Macrolides with activity against methicillin-resistant staphylococcus aureus |
JP2005520566A (ja) * | 2002-03-22 | 2005-07-14 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Cripto特異的抗体 |
ATE437950T1 (de) * | 2003-09-15 | 2009-08-15 | Res Dev Foundation | Cripto-antagonismus von activin und tgf-b signalisierung |
EP2311880A3 (en) | 2005-01-05 | 2011-07-27 | Biogen Idec MA Inc. | Cripto binding molecules |
CN101479391A (zh) | 2006-04-28 | 2009-07-08 | 比奥根艾迪克Ma公司 | 用于检测cripto-3的组合物及方法 |
-
2002
- 2002-04-17 DE DE60230868T patent/DE60230868D1/de not_active Expired - Lifetime
- 2002-04-17 AT AT02731384T patent/ATE420659T1/de active
- 2002-04-17 SG SG200600551-6A patent/SG157951A1/en unknown
- 2002-04-17 SK SK1443-2003A patent/SK14432003A3/sk not_active Application Discontinuation
- 2002-04-17 RS RS20110024A patent/RS20110024A/en unknown
- 2002-04-17 SI SI200230804T patent/SI1390389T1/sl unknown
- 2002-04-17 WO PCT/US2002/011950 patent/WO2002088170A2/en active Search and Examination
- 2002-04-17 ES ES02731384T patent/ES2321065T3/es not_active Expired - Lifetime
- 2002-04-17 CA CA2715570A patent/CA2715570A1/en not_active Abandoned
- 2002-04-17 EP EP08158456A patent/EP1974749B1/en not_active Expired - Lifetime
- 2002-04-17 EP EP10186149A patent/EP2316486A3/en not_active Withdrawn
- 2002-04-17 DK DK02731384T patent/DK1390389T3/da active
- 2002-04-17 MX MXPA03009797A patent/MXPA03009797A/es active IP Right Grant
- 2002-04-17 PL PL373513A patent/PL207087B1/pl unknown
- 2002-04-17 CN CNB028128877A patent/CN100352501C/zh not_active Expired - Fee Related
- 2002-04-17 EP EP02731384A patent/EP1390389B1/en not_active Expired - Lifetime
- 2002-04-17 KR KR1020037014078A patent/KR100592357B1/ko not_active IP Right Cessation
- 2002-04-17 EE EEP200300528A patent/EE200300528A/xx unknown
- 2002-04-17 TR TR2003/01846T patent/TR200301846T2/xx unknown
- 2002-04-17 PT PT02731384T patent/PT1390389E/pt unknown
- 2002-04-17 HU HU0501113A patent/HUP0501113A3/hu unknown
- 2002-04-17 CZ CZ20033208A patent/CZ20033208A3/cs unknown
- 2002-04-17 GE GE5415A patent/GEP20074091B/en unknown
- 2002-04-17 NZ NZ566268A patent/NZ566268A/en not_active IP Right Cessation
- 2002-04-17 BR BRPI0209254-9A patent/BR0209254A/pt not_active IP Right Cessation
- 2002-04-17 AT AT08158456T patent/ATE533508T1/de active
- 2002-04-17 RS YU84903A patent/RS51635B/sr unknown
- 2002-04-17 EA EA200301158A patent/EA007469B1/ru not_active IP Right Cessation
- 2002-04-17 CA CA2443840A patent/CA2443840C/en not_active Expired - Fee Related
- 2002-04-17 JP JP2002585468A patent/JP4307845B2/ja not_active Expired - Fee Related
- 2002-04-23 MY MYPI20021484A patent/MY157382A/en unknown
- 2002-04-23 MY MYPI2010003173A patent/MY150237A/en unknown
- 2002-04-24 AR ARP020101492A patent/AR037223A1/es active IP Right Grant
-
2003
- 2003-10-23 US US10/693,538 patent/US7531174B2/en not_active Expired - Lifetime
- 2003-10-24 IS IS6999A patent/IS2662B/is unknown
- 2003-10-27 NO NO20034805A patent/NO20034805L/no not_active Application Discontinuation
- 2003-11-14 BG BG108363A patent/BG108363A/bg unknown
-
2004
- 2004-03-11 HK HK04101788.0A patent/HK1058935A1/xx not_active IP Right Cessation
-
2005
- 2005-07-11 JP JP2005202361A patent/JP2005314436A/ja active Pending
-
2007
- 2007-04-30 US US11/799,361 patent/US7674462B2/en not_active Expired - Lifetime
-
2008
- 2008-12-22 US US12/317,476 patent/US8003763B2/en not_active Expired - Lifetime
-
2009
- 2009-01-14 US US12/353,913 patent/US20090285818A1/en not_active Abandoned
- 2009-02-05 JP JP2009025420A patent/JP4575983B2/ja not_active Expired - Fee Related
- 2009-03-31 US US12/415,659 patent/US7888052B2/en not_active Expired - Lifetime
- 2009-04-08 CY CY20091100413T patent/CY1108960T1/el unknown
- 2009-07-08 AR ARP090102597A patent/AR072554A2/es not_active Application Discontinuation
- 2009-12-22 CL CL2009002199A patent/CL2009002199A1/es unknown
-
2010
- 2010-02-15 JP JP2010030683A patent/JP2010163438A/ja not_active Withdrawn
- 2010-07-16 AR ARP100102604A patent/AR077759A2/es not_active Application Discontinuation
-
2011
- 2011-08-19 US US13/213,499 patent/US8673303B2/en not_active Expired - Lifetime
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010163438A5 (ja) | ||
US11891436B2 (en) | Monoclonal antibodies to growth and differentiation factor 15 (GDF-15) | |
HRP20192347T1 (hr) | Antitijela prema klaudinu 18.2 koja su korisna u dijagnozi tumora | |
HRP20180262T1 (hr) | Monoklonska anti-gt468 protutijela za liječenje karcinoma | |
JP2004534020A5 (ja) | ||
JP2009108100A5 (ja) | ||
ES2927090T3 (es) | Anticuerpo anti-TROP-2 humano que muestra actividad antitumoral in vivo | |
ES2664809T3 (es) | Anticuerpo anti-TROP-2 humano que tiene actividad antitumoral in vivo | |
CA2443840A1 (en) | Cripto blocking antibodies and uses thereof | |
ES2528132T3 (es) | Método para diagnosticar cánceres que expresan el receptor HER2 o sus variantes truncadas | |
RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
JP2016187356A5 (ja) | ||
WO2012135854A3 (en) | T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2 | |
RU2011111746A (ru) | Композиции рекомбинантных антител против рецептора эпидермального фактора роста | |
JP2007536932A5 (ja) | ||
ES2527143T3 (es) | Anticuerpos frente a variante truncada CTF-611 de HER2 | |
JP2012523848A5 (ja) | ||
JP2010508847A5 (ja) | ||
JP2010111679A5 (ja) | ||
WO2007145840A3 (en) | Compositions and methods for diagnosing and treating cancer | |
NZ713461A (en) | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer | |
CA2621363A1 (en) | Methods and compositions for modulating tumor cell activity | |
MX2009009450A (es) | Anticuerpos monoclonales para he4 y metodos para su uso. | |
JP2010006705A5 (ja) | ||
JP2020503252A5 (ja) |